{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:57:24Z","timestamp":1793170644070,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rmed.2024.107863","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T14:30:59Z","timestamp":1731767459000},"page":"107863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis"],"prefix":"10.1016","volume":"236","author":[{"given":"Ambanna","family":"Yappalparvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Balaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Padmapriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gaidhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwanjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaib","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.V. Siva","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atreyi","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teena","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Promila","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Punia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Jagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doddolla","family":"Lingamaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjit","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-899X","authenticated-orcid":false,"given":"Quazi Syed","family":"Zahiruddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-2188","authenticated-orcid":false,"given":"Hashem","family":"Abu Serhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Shabil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Bushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2024.107863_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","author":"Soriano","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2024.107863_bib2","series-title":"Chronic Obstructive Pulmonary Disease","author":"Agarwal","year":"2020"},{"issue":"7551","key":"10.1016\/j.rmed.2024.107863_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.332.7551.1202","article-title":"Pathology, pathogenesis, and pathophysiology","volume":"332","author":"MacNee","year":"2006","journal-title":"Br. Med. J."},{"issue":"5","key":"10.1016\/j.rmed.2024.107863_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2040622314532862","article-title":"Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications","volume":"5","author":"Qureshi","year":"2014","journal-title":"Therapeut. Advan. Chronic Disease"},{"issue":"1","key":"10.1016\/j.rmed.2024.107863_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13052-024-01675-0","article-title":"Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases","volume":"50","author":"Licari","year":"2024","journal-title":"Ital. J. Pediatr."},{"issue":"7","key":"10.1016\/j.rmed.2024.107863_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2022.101483","article-title":"Current limitations and recent advances in the management of asthma","volume":"69","author":"Patel","year":"2023","journal-title":"Disease-a-Month"},{"key":"10.1016\/j.rmed.2024.107863_bib7","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/COPD.S413436","article-title":"Ensifentrine as a novel, inhaled treatment for patients with COPD","author":"Donohue","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2024.107863_bib8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2147\/COPD.S307160","article-title":"A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy","author":"Ferguson","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2024.107863_bib9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2024.107863_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1164\/rccm.202307-1143LE","article-title":"Inhaled dual PDE3\/4 inhibitor ensifentrine for chronic obstructive pulmonary disease: a potential therapeutic perspective","volume":"209","author":"Gan","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2024.107863_bib11","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med."},{"key":"10.1016\/j.rmed.2024.107863_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jclinepi.2020.06.015","article-title":"The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application","volume":"126","author":"Minozzi","year":"2020","journal-title":"J. Clin. Epidemiol."},{"issue":"16","key":"10.1016\/j.rmed.2024.107863_bib13","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40265-021-01616-9","article-title":"Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"81","author":"Singh","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2024.107863_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2147\/COPD.S226688","article-title":"Inhaled dual phosphodiesterase 3\/4 inhibitors for the treatment of patients with COPD: a short review","author":"Martin","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2024.107863_bib15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/COPD.S440252","article-title":"The dosing strategy to improve adherence to roflumilast in treatment for chronic obstructive lung disease: a systemic review and meta-analysis","author":"Lee","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2024.107863_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2024.08.002","article-title":"Ensifentrine (Ohtuvayre\u2122) for chronic obstructive pulmonary disease","author":"Hubert","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.rmed.2024.107863_bib17","first-page":"1","article-title":"Update on the pharmacological treatment of chronic obstructive pulmonary disease","author":"Jacques","year":"2024","journal-title":"Expet Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.rmed.2024.107863_bib18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107863_bib19","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2147\/COPD.S226688","article-title":"Inhaled dual phosphodiesterase 3\/4 inhibitors for the treatment of patients with COPD: a short review","volume":"16","author":"Martin","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2024.107863_bib20","author":"Organization"},{"key":"10.1016\/j.rmed.2024.107863_bib21","doi-asserted-by":"crossref","first-page":"A4296","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4296","article-title":"Ensifentrine, A novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation in COPD when administered twice daily over 7 Days via a dry powder inhaler","author":"Rheault","year":"2020","journal-title":"B103 Treat. Obstruct. Lung Disease: Am. Thoracic Soci."},{"issue":"4","key":"10.1016\/j.rmed.2024.107863_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1164\/rccm.202307-1164ED","article-title":"A new treatment for chronic obstructive pulmonary disease: ensifentrine moves closer","volume":"208","author":"Singh","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.rmed.2024.107863_bib23","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.18553\/jmcp.2024.30.11.1338","article-title":"The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease: a summary from the institute for clinical and economic review's midwest comparative effectiveness public advisory council","volume":"30","author":"Wright","year":"2024","journal-title":"J. Manag. Care Specialt. Pharm."},{"issue":"8","key":"10.1016\/j.rmed.2024.107863_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/17476348.2024.2389960","article-title":"Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials","volume":"18","author":"Mahler","year":"2024","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.rmed.2024.107863_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-020-1307-4","article-title":"A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD","volume":"21","author":"Singh","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2024.107863_bib26","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/COPD.S263025","article-title":"Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD\u2013a detailed analysis","author":"Watz","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112400338X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112400338X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:01:06Z","timestamp":1738879266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112400338X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"alternative-id":["S095461112400338X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107863","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107863"}}